ID: ALA5198165

Max Phase: Preclinical

Molecular Formula: C53H89N21O17

Molecular Weight: 1292.43

Representations

Canonical SMILES:  C[C@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(N)=O)[C@@H](C)O

Standard InChI:  InChI=1S/C53H89N21O17/c1-25(55)44(82)69-30(14-11-21-63-53(59)60)47(85)71-29(45(83)70-28(12-6-8-18-54)46(84)72-31(16-17-33(56)76)48(86)73-36(27(3)75)49(87)67-26(2)42(58)81)13-7-10-19-61-35(78)22-32(52(89)90)68-34(77)15-5-4-9-20-62-50(88)40-38(79)39(80)51(91-40)74-24-66-37-41(57)64-23-65-43(37)74/h23-32,36,38-40,51,75,79-80H,4-22,54-55H2,1-3H3,(H2,56,76)(H2,58,81)(H,61,78)(H,62,88)(H,67,87)(H,68,77)(H,69,82)(H,70,83)(H,71,85)(H,72,84)(H,73,86)(H,89,90)(H2,57,64,65)(H4,59,60,63)/t25-,26-,27+,28-,29-,30-,31-,32+,36-,38-,39+,40-,51+/m0/s1

Standard InChI Key:  DZKZPXDNPVSTLC-RMMWAGDVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1292.43

Molecular Weight (Monoisotopic): 1291.6745

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Lee S, Kim J, Jo J, Chang JW, Sim J, Yun H..  (2021)  Recent advances in development of hetero-bivalent kinase inhibitors.,  216  [PMID:33730624] [10.1016/j.ejmech.2021.113318]

Source

Source(1):

• Scientific Literature